Mazdutide
Aliases: IBI362 · OXM3 · GLP-1/GCGR dual agonist
Mazdutide is a linear peptide targeting GLP-1R, Glucagon receptor, developed by Eli Lilly for multiple indications. As of Aug 15, 2024, its highest verified stage is Phase 3.
Phase 3· verified Aug 15, 2024
Identity
- Generic name
- —
- Brand names
- —
- Development codes
- IBI362, LY3305677
- Sponsor / originator
- Eli Lilly
- Targets
- GLP-1RGlucagon receptor
- Route / formulation
- Subcutaneous injection
Development timeline
- Phase 3· Obesity· China
As of Aug 15, 2024 · Confidence: medium
Trials
View all →No records found.